Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study.
Lingfang XiaJin PengGe LouMei PanQi ZhouWenjing HuHuirong ShiLi WangYunong GaoJian Qing ZhuYu ZhangRong SunXianfeng ZhouQuanren WangXiaohua WuPublished in: Journal for immunotherapy of cancer (2022)
NCT03827837.
Keyphrases